{"classes":["LITERATURE REFERENCE","PRIMARYSOURCECOUNTRY","REPORTERORGANIZATION","REPORTERCOUNTRY","PATIENTONSETAGE","PATIENTSEX","RESULTSTESTSPROCEDURES","PATIENTDRUGNAME","PATIENTDRUGINDICATION","PATIENTDRUGREACTION","PRIMARYSOURCEREACTION","MEDICINALPRODUCT","REPORTERDEPARTMENT","PATIENTDEATHREPORT","REACTIONSTARTDATE","PATIENTAGEGROUP","SERIOUSNESSOTHER","SERIOUSNESSHOSPITALIZATION","REPORTERGIVENAME","REPORTERFAMILYNAME","REPORTERSTREET","REPORTERCITY","REPORTERPOSTCODE","TESTNAME","TESTRESULT","DRUGDOSAGEFORM","DRUGADMINISTRATIONROUTE","DRUGINDICATION","DRUGSTARTPERIODUNIT","SERIOUSNESSLIFETHREATENING","TESTUNIT","MEDICALHISTORYEPISODE","PATIENTPASTDRUGTHERAPY","DRUGSTRUCTUREDOSAGEUNIT","REPORTERMIDDLENAME","REPORTERSTATE","SERIOUSNESSDEATH","ACTIONDRUG","DRUGDOSAGETEXT","DRUGSTRUCTUREDOSAGENUMB","PATIENTWEIGHT","SUSPECTPRODUCT","CONCOMITANTPRODUCT","PATIENTHEIGHT","DRUGINTERVALDOSAGEDEFINITION","INTERACTINGPRODUCT","PATIENTMEDICALHISTORYTEXT","PASTDRUGNAME","PATIENTMEDICALSTARTDATE","REACTIONENDDATE"],"annotations":[["Nowdays there are different strategies for the treatment of smoking cessation. The treatment include drugs such as varenicline, which acts as a high-affinity partial agonist for the alpha-4 beta-2 nicotinic acetylcholine receptor subtype (nACh). We report a case of a suicidal behaviour in a 39 year-old woman with no previous history of mental illness, who was brought to the emergency department after intentional intoxication with benzodiazepines. The patient was on 10th day of treatment with varenicline.\r\nTo present a case of sucidal behavior that developed in a 39 year-old woman after starting varenicline. Review of literature and total number of cases reported in the european database of suspected adverse drug reactions (EudraVigilance).\r\nWe carried out a literature review in Pubmed electing those articles focused on mental disorders in those patients that have been taking varenicline. Review number of cases suicidal behavior reported by the European database of suspected adverse drug reactions.\r\nA 39-year-old female was brought to the emergency department after voluntary ingestion of Lorazepam 1mg (40 tablets) in a sucide attempt. The family reported the starting of thoughts of suicide after 1 week of treatment. No previous history of mental disorders. The patient reported low mood and drowsiness in the last 5 days not linked to any cause. After 5 days of discontinuation these mood symptoms and sucidal behavior remited.\r\nVarenicline is associated with different neuropsychiatric sypmtoms. In patients with or without history of mental disorders we should warn about the symptoms for discontinuation of the treatment.\r\n\r\n\r\nGutierrez Higueras T, Calera Cortes F, Sainz De La Cuesta Alonso S, Vicent Fores S, Hernandez Gajate B, Fiestas Velasco RM. Varenicline-induced sucidal behavior: Case report and literature review. European Psychiatry. 2022;65(Supplement 1):S715. DOI: 10.1192/j.eurpsy.2022.1844\r\n\r\nThis case was detected in the medical literature by the EMA MLM Service from Gutierrez Higueras T, Calera Cortes F, Sainz De La Cuesta Alonso S, Vicent Fores S, Hernandez Gajate B, Fiestas Velasco RM. Varenicline-induced sucidal behavior: Case report and literature review. European Psychiatry. 2022;65(Supplement 1):S715 on 09 Dec 2022. The above citation is from a conference abstract. This spontaneous case was reported in the medical literature by a physician from Spain and concerns a 39-year-old female patient who experienced a serious adverse reaction of intentional intoxication with Lorazepam. The author presented a case of suicidal behavior that developed in a woman after starting varenicline and was brought to the emergency department after intentional intoxication with benzodiazepines. The patient was brought to the emergency department after voluntary ingestion of Lorazepam 1mg (40 tablets) in a suicide attempt. The patient was on 10th day of treatment with varenicline. The family reported the starting of thoughts of suicide after 1 week of treatment. No previous history of mental disorders. The patient reported low mood and drowsiness in the last 5 days not linked to any cause. After 5 days of discontinuation these mood symptoms and suicidal behavior remitted. Follow-up has not been requested because we do not have contact details for the author.",{"entities":[[60,78,"DRUGINDICATION"],[569,580,"PATIENTONSETAGE"],[581,586,"PATIENTSEX"],[1310,1320,"MEDICALHISTORYEPISODE"],[1649,1667,"REPORTERFAMILYNAME"],[1668,1669,"REPORTERGIVENAME"],[1671,1854,"LITERATURE REFERENCE"],[1855,1866,"REPORTERDEPARTMENT"],[1867,1926,"LITERATURE REFERENCE"],[2493,2533,"PRIMARYSOURCEREACTION"],[2814,2823,"SUSPECTPRODUCT"],[2829,2831,"DRUGSTRUCTUREDOSAGENUMB"],[2846,2862,"DRUGINDICATION"],[2909,2921,"CONCOMITANTPRODUCT"],[3067,3075,"MEDICALHISTORYEPISODE"],[3191,3208,"MEDICALHISTORYEPISODE"]]}],["Nowdays there are different strategies for the treatment of smoking cessation. The treatment include drugs such as varenicline, which acts as a high-affinity partial agonist for the alpha-4 beta-2 nicotinic acetylcholine receptor subtype (nACh). We report a case of a suicidal behaviour in a 39 year-old woman with no previous history of mental illness, who was brought to the emergency department after intentional intoxication with benzodiazepines. The patient was on 10th day of treatment with varenicline.\r\nTo present a case of sucidal behavior that developed in a 39 year-old woman after starting varenicline. Review of literature and total number of cases reported in the european database of suspected adverse drug reactions (EudraVigilance).\r\nWe carried out a literature review in Pubmed electing those articles focused on mental disorders in those patients that have been taking varenicline. Review number of cases suicidal behavior reported by the European database of suspected adverse drug reactions.\r\nA 39-year-old female was brought to the emergency department after voluntary ingestion of Lorazepam 1mg (40 tablets) in a sucide attempt. The family reported the starting of thoughts of suicide after 1 week of treatment. No previous history of mental disorders. The patient reported low mood and drowsiness in the last 5 days not linked to any cause. After 5 days of discontinuation these mood symptoms and sucidal behavior remited.\r\nVarenicline is associated with different neuropsychiatric sypmtoms. In patients with or without history of mental disorders we should warn about the symptoms for discontinuation of the treatment.\r\n\r\n\r\nGutierrez Higueras T, Calera Cortes F, Sainz De La Cuesta Alonso S, Vicent Fores S, Hernandez Gajate B, Fiestas Velasco RM. Varenicline-induced sucidal behavior: Case report and literature review. European Psychiatry. 2022;65(Supplement 1):S715. DOI: 10.1192/j.eurpsy.2022.1844\r\n\r\nThis case was detected in the medical literature by the EMA MLM Service from Gutierrez Higueras T, Calera Cortes F, Sainz De La Cuesta Alonso S, Vicent Fores S, Hernandez Gajate B, Fiestas Velasco RM. Varenicline-induced sucidal behavior: Case report and literature review. European Psychiatry. 2022;65(Supplement 1):S715 on 09 Dec 2022. The above citation is from a conference abstract. This spontaneous case was reported in the medical literature by a physician from Spain and concerns a 39-year-old female patient who experienced a serious adverse reaction of intentional intoxication with Lorazepam. The author presented a case of suicidal behavior that developed in a woman after starting varenicline and was brought to the emergency department after intentional intoxication with benzodiazepines. The patient was brought to the emergency department after voluntary ingestion of Lorazepam 1mg (40 tablets) in a suicide attempt. The patient was on 10th day of treatment with varenicline. The family reported the starting of thoughts of suicide after 1 week of treatment. No previous history of mental disorders. The patient reported low mood and drowsiness in the last 5 days not linked to any cause. After 5 days of discontinuation these mood symptoms and suicidal behavior remitted. Follow-up has not been requested because we do not have contact details for the author.",{"entities":[[60,78,"DRUGINDICATION"],[569,580,"PATIENTONSETAGE"],[581,586,"PATIENTSEX"],[1310,1320,"MEDICALHISTORYEPISODE"],[1649,1667,"REPORTERFAMILYNAME"],[1668,1669,"REPORTERGIVENAME"],[1671,1854,"LITERATURE REFERENCE"],[1855,1866,"REPORTERDEPARTMENT"],[1867,1926,"LITERATURE REFERENCE"],[2493,2533,"PRIMARYSOURCEREACTION"],[2814,2823,"SUSPECTPRODUCT"],[2829,2831,"DRUGSTRUCTUREDOSAGENUMB"],[2846,2862,"DRUGINDICATION"],[2909,2921,"CONCOMITANTPRODUCT"],[3067,3075,"MEDICALHISTORYEPISODE"],[3191,3208,"MEDICALHISTORYEPISODE"]]}]]}